Pharminent · Daily Brief
October 7, 2026
Regulatory & Approvals
FDA approves Click’s digital therapeutic Motivista for schizophrenia
Click Therapeutics said it received the first-ever FDA approval of a treatment for the negative symptoms of schizophrenia, a digital therapeutic called Motivista.
Pharmaphorum →
Clinical Data
AbbVie and Genmab’s Epkinly succeeds in frontline DLBCL trial
AbbVie and Genmab reported positive results from the EPCORE trial of the bispecific antibody Epkinly in newly diagnosed diffuse large B-cell lymphoma.
BioPharma Dive →$ABBV
ArriVent shares fall by half on furmonertinib lung cancer data
More than half of ArriVent’s market value was wiped out after the company reported results for furmonertinib in EGFR-mutated lung cancer.
BioPharma Dive →
Amplio reports Phase 1b data for NovoBioJect in rheumatoid arthritis
Amplio Pharma reported Phase 1b results for NovoBioJect, a combination of low-dose methotrexate and novobiocin being developed as a potential first-line treatment for rheumatoid arthritis; in the 12-patient study, a single dose produced a 38% increase in intracellular long-chain methotrexate polyglutamates (MTX-PG4 and MTX-PG5) compared with methotrexate alone.
PharmaFile →
Deals & Partnerships
Gilead signs five-year DevOps agreement extension with Cognizant
Gilead Sciences signed a five-year agreement extension with Cognizant to advance its DevOps environment and support deployment of agentic AI tools across designated technology initiatives.
Pharmaceutical Technology →$GILD
Business & Finance
Caribou Biosciences shutting down after failing to raise funds
Caribou Biosciences, co-founded by Jennifer Doudna, is shutting down after failing to raise the money needed to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.
STAT →
Adecto and Aviceda wind down operations
Biotechs Adecto and Aviceda are winding down their operations, while Caribou is in peril.
Pharmaphorum →
AstraZeneca opens new R&D site in Cambridge, Massachusetts
AstraZeneca opened a new R&D site in Kendall Square in Cambridge, Massachusetts, the centerpiece of a $1 billion investment in the state.
STAT →$AZN
KymaThera raises $80M Series B for breast cancer drug
KymaThera raised $80 million in a Series B financing and plans to dose the first patients in a Phase I trial of K-1728, an oral selective PI3K-alpha inhibitor, in breast cancer in the fourth quarter of 2026.
Pharmaceutical Technology →
Rocket secures $150M credit facility from Hercules Capital
Rocket Pharmaceuticals entered into a credit facility agreement of up to $150 million with Hercules Capital to support ongoing development of its cardiovascular portfolio.
Pharmaceutical Technology →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.